In recent years we have seen a slow but steady paradigm shift in how pharmaceutical companies approach early drug discovery. The role of discovery partnerships in a high-failure-rate industry such as bio/pharma is thus pivotal for enhancing innovation while de-risking in the pre-clinical stages. In this interview Kristof Van Emelen, Scientific Director - Partnership Integrator for Janssen Pharmaceutica N.V., speaks to Andrea Charles from Pharma IQ about impact of the rise of global innova...
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More